Tarsheen Sethi, MD, MSc
Assistant Professor of Medicine (Hematology)DownloadHi-Res Photo
Cards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Director, Yale Affiliated Hospital Program for Hematology Section, Internal Medicine
Contact Info
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Director, Yale Affiliated Hospital Program for Hematology Section, Internal Medicine
Contact Info
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Director, Yale Affiliated Hospital Program for Hematology Section, Internal Medicine
Contact Info
About
Copy Link
Titles
Assistant Professor of Medicine (Hematology)
Director, Yale Affiliated Hospital Program for Hematology Section, Internal Medicine
Biography
Tarsheen Sethi, MD, MSCI, is an Assistant Professor of Medicine (Hematology) and cares primarily for patients with Hodgkin and Non-Hodgkin lymphomas. Under the mentorship of Dr. Francine Foss, Dr. Sethi sees patients of all lymphoma subtypes, including T-cell lymphomas and Chronic Leukocytic Leukemia. Dr. Sethi joined Smilow from Vanderbilt University Medical School where she was an Instructor of Medicine in their Division of Hematology-Oncology.
Dr. Sethi received her Medical Degree from the Maulana Azad Medical College in New Delhi, India, and her Master of Science in Clinical Investigation at Vanderbilt University, where she also completed her fellowship in Hematology-Oncology. As a post-doctoral research fellow at the Stanford Molecular Imaging Program, Dr. Sethi received the Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation Award in Translational Medicine and Therapeutics. With this research training background, she is involved in clinical and translational research projects aimed at improving care and outcomes of Hodgkin and Non-Hodgkin lymphoma patients. Dr. Sethi’s research includes clinical trials targeting lymphomas involving novel drugs and combinations. She is also interested in studying the applications of tumor immunology and immunotherapy to hematologic malignancies, focusing on lymphoma.
Last Updated on April 07, 2025.
Appointments
Medical Oncology and Hematology
Assistant ProfessorPrimary
Other Departments & Organizations
- Hematology
- Internal Medicine
- Leukemia & Lymphoma Program
- Medical Oncology and Hematology
- Yale Cancer Center
- Yale Medicine
Education & Training
- Clinical Fellow and Advanced Fellow
- Vanderbilt University Medical Center (2018)
- MSc
- Vanderbilt University, Clinical Investigation (2018)
- Intern and Resident Physician
- University of Louisville (2013)
- Chief Resident
- Maulana Azad Medical College (2009)
- MD
- Maulana Azad Medical College (2008)
- Resident Physician
- Maulana Azad Medical College (2008)
- MBBS
- Maulana Azad Medical College (2005)
Research
Copy Link
Overview
Her research is aimed at improving care and outcomes of Hodgkin and Non-Hodgkin lymphoma patients. She is also interested in studying the applications of tumor immunology and immunotherapy to hematologic malignancies focusing on lymphoma.
Medical Research Interests
Hodgkin Disease; Lymphoma
ORCID
0000-0002-1346-2103
Research at a Glance
Yale Co-Authors
Frequent collaborators of Tarsheen Sethi's published research.
Publications Timeline
A big-picture view of Tarsheen Sethi's research output by year.
Research Interests
Research topics Tarsheen Sethi is interested in exploring.
Shalin Kothari, MD
Francine Foss, MD
Scott Huntington, MD, MPH, MSc
Iris Isufi, MD
Stuart Seropian, MD
Michael Girardi, MD, FAAD
67Publications
453Citations
Lymphoma
Publications
2025
Early discharge program cost savings for patients with newly diagnosed acute myeloid leukemia after intensive induction chemotherapy
Hunter C, Chetlapalli K, Ito S, Bewersdorf J, Boddu P, Browning S, Halene S, Parker T, Huntington S, Kothari S, Mendez L, Neparidze N, Sethi T, Stahl M, Podoltsev N, Zeidan A, Shallis R, Goshua G. Early discharge program cost savings for patients with newly diagnosed acute myeloid leukemia after intensive induction chemotherapy. Blood 2025, 146: 6208. DOI: 10.1182/blood-2025-6208.Peer-Reviewed Original ResearchConceptsEarly discharge programAbsolute neutrophil countLow absolute neutrophil countAcute myeloid leukemiaNext therapyIntensive chemotherapyTraditional cohortDirect costsHospital dischargeMyeloid leukemiaDirect costs of careOutpatient clinical careLonger hospitalInpatient bed usePatient's absolute neutrophil countDays of antimicrobial therapyCohort of consecutive patientsCost of careRed blood cell transfusionProgram cost savingsAssociated with longer hospitalSecond-line therapyBlood cell transfusionKaplan-Meier methodRisk exposure periodPrognostic impact of cytogenetic abnormalities in aggressive T-cell lymphomas: Defining high-risk subgroups through conventional karyotyping.
Kiwan A, Diadamo A, Wen J, Kewan T, Siddon A, Kothari S, Isufi I, Seropian S, Huntington S, Montanari F, Xu M, Li P, Girardi M, Sethi T, Foss F. Prognostic impact of cytogenetic abnormalities in aggressive T-cell lymphomas: Defining high-risk subgroups through conventional karyotyping. Blood 2025, 146: 1759-1759. DOI: 10.1182/blood-2025-1759.Peer-Reviewed Original ResearchConceptsT-cell lymphomaMature T-cell lymphomasAggressive T-cell lymphomaUnivariate Cox proportional hazardsMonosomy 9Overall survivalPeripheral bloodMonosomy 5Nodal PTCLBone marrowHigh-risk subgroupsPrognostic significancePlatelet countCox proportional hazardsCytogenetic abnormalitiesPrognostic impactComplex karyotypeT cellsMarker chromosomesPrognostic impact of cytogenetic abnormalitiesPredictor of poor OSImpact of cytogenetic abnormalitiesMultivariate CPH modelChromosomal lesionsPresence of marker chromosomesAllogeneic stem cell transplant results in t-cell prolymphocytic leukemia (T-PLL): A collaborative multi-center study cohort
Braunstein Z, McLaughlin E, Lingamaneni P, Barta S, Cao M, Chang T, Ganesan N, Shree T, Luu B, Mehta-Shah N, Watkins M, Zain J, Allen P, Paulino D, Adams B, Wang J, Feng A, Marchi E, Roberts N, Wilcox R, Gutierrez M, Frosch Z, Sklarz T, Sethi T, Foss F, Beaven A, Haverkos B, Treitman R, Oh T, Moreira J, Reilly S, Khoo A, Porcu P, Kataria A, Jagadeesh D, Carlson A, Rajguru S, Babu A, Zhang X, Mishra A, Stuver R, Poh C, Hampel P, Brammer J. Allogeneic stem cell transplant results in t-cell prolymphocytic leukemia (T-PLL): A collaborative multi-center study cohort. Blood 2025, 146: 1054-1054. DOI: 10.1182/blood-2025-1054.Peer-Reviewed Original ResearchAltmetricConceptsT-cell prolymphocytic leukemiaProgression-free survivalMinimal residual diseaseT-PLL patientsCD4-CD8+Overall survivalMyeloablative conditioningPost-alloSCTCD4-CD8Incidence of grade II-IV acute GVHDGrade II-IV acute GVHDHigher rate of relapseMinimal residual disease positivityAllogeneic stem cell transplantationMedian follow-up timeMonths post-alloSCTMulti-center seriesNational cohort of patientsStem cell transplantationDisease subtypesNational cohortKaplan-Meier methodCohort of patientsFollow-up timeSignificant survival differenceReal-world outcomes of glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) in Relapsed/Refractory (R/R) aggressive B-cell lymphoma (BCL): A multicenter retrospective study from the United States
Tiger Y, Asrani R, Wehmeyer G, Ryan R, Major A, Grover N, Baron K, Hilal T, Nedved A, Brooks T, Ravishankar A, Sethi T, Hill B, Wang Y, Bock A, Kittai A, Matasar M, Rhodes J. Real-world outcomes of glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) in Relapsed/Refractory (R/R) aggressive B-cell lymphoma (BCL): A multicenter retrospective study from the United States. Blood 2025, 146: 1956-1956. DOI: 10.1182/blood-2025-1956.Peer-Reviewed Original ResearchConceptsAggressive B-cell lymphomasR/R aggressive B-cell lymphomaB-cell lymphomaTreatment-related deathsFollicular lymphomaCR rateCAR-TCD20 expressionBurkitt's lymphomaBridging therapyReal-world analysisDays of CAR T-cell infusionR/R large B-cell lymphomaHigh-grade B-cell lymphomaGerminal center B-cell phenotypeCAR-T cell infusionCAR-T cell therapyLarge B-cell lymphomaMedian ECOG performance statusOncologic Drugs Advisory CommitteeFDA's Oncologic Drugs Advisory CommitteeMedian 4 cyclesPost-CAR-TT-cell infusionT-cell therapyRacial and socioeconomic disparities in clinical trial participation and outcomes in systemic peripheral T-cell lymphoma (PTCL): A multicenter retrospective Study
Sanjurjo A, DeStephano D, Kahn J, Beauchemin M, Gribbin C, Toor R, Ruan J, Meza K, Edelman Saul E, Valcarcel B, Malpica L, Seymour K, Li N, Sica R, Nayak R, Allen P, Subramanian M, Tiger Y, Lyubimova A, Santos-Carrion L, Romagnoli C, Barrientos J, Ruiz M, Brammer J, Qureshi H, Foss F, Sethi T, Elghawy O, Barta S, Cherng H, Pro B, Amengual J, Tolu S. Racial and socioeconomic disparities in clinical trial participation and outcomes in systemic peripheral T-cell lymphoma (PTCL): A multicenter retrospective Study. Blood 2025, 146: 4523-4523. DOI: 10.1182/blood-2025-4523.Peer-Reviewed Original ResearchConceptsNon-Hispanic black patientsSocial deprivation indexNon-Hispanic blacksHigher social deprivation indexNHW patientsSocioeconomic statusPeripheral T-cell lymphomaSystemic peripheral T-cell lymphomasClinical trial participationTrial participantsCharlson Comorbidity IndexHispanic patientsTrial enrollmentIncome quintileMulticenter retrospective studyTrial eligibilitySystem-level barriersT-cell lymphomaOverall survivalSocioeconomic status disparitiesLowest income quintileStudy of adultsMultivariate analysisComplete remissionDiagnosis to deathConcurrent TP53 loss-of-function and epigenetic modifier mutations as a potential predictor of chemoimmunotherapy failure in DLBCL & hgbl
Ravishankar A, Isufi I, Huntington S, Seropian S, Foss F, Sethi T, Kothari S. Concurrent TP53 loss-of-function and epigenetic modifier mutations as a potential predictor of chemoimmunotherapy failure in DLBCL & hgbl. Blood 2025, 146: 7071-7071. DOI: 10.1182/blood-2025-7071.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaHigh-grade B-cell lymphomaCell of originChimeric antigen receptorCAR-T therapyComprehensive genomic profilingB-cell lymphomaFirst-line therapyTP53 mutationsCAR-TClinicopathological variablesAssociated with failureLoss-of-functionIPI scoreCR patientsPerformance statusRearrangement statusResponse to first-line therapyGenomic profilingAllogeneic stem cell transplantationLarge B-cell lymphomaMarker of poor prognosisAnthracycline-based chemoimmunotherapyDiagnostic tumor samplesStatus of MYCApplication of hi-c sequencing to detect cryptic and novel structural aberrations in lymphoid neoplasms
Rozenova K, Sethi T, Kumar D, Braddock D, Xu M. Application of hi-c sequencing to detect cryptic and novel structural aberrations in lymphoid neoplasms. Blood 2025, 146: 4355. DOI: 10.1182/blood-2025-4355.Peer-Reviewed Original ResearchConceptsFluorescence in situ hybridizationB-cell lymphomaHigh-grade B-cell lymphomaDiffuse large B-cell lymphomaFormalin-fixed-paraffin-embeddedFluorescence in situ hybridization studiesHi-C sequencingHi-CBurkitt's lymphomaMYC rearrangementDNA segmentsLymphoid malignanciesLymphoid neoplasmsStructural variantsHigh-throughput chromosome conformation captureDetection of structural rearrangementsHistory of invasive breast carcinomaBreak-apart fluorescence in situ hybridizationAxillary lymph node biopsyDiagnosis of Burkitt's lymphomaClinical response to therapyLarge B-cell lymphomaHi-C analysisSequenced DNA segmentsChromosome conformation captureAberrant circulating CD4+ CD26- T-cells in T-cell rich B-cell lymphomas: Diagnostic pitfall or biomarker?
Ravishankar A, Chen P, Xu M, Braddock D, Siddon A, Isufi I, Huntington S, Seropian S, Foss F, Kothari S, Sethi T. Aberrant circulating CD4+ CD26- T-cells in T-cell rich B-cell lymphomas: Diagnostic pitfall or biomarker? Blood 2025, 146: 7182. DOI: 10.1182/blood-2025-7182.Peer-Reviewed Original ResearchConceptsNodular lymphocyte-predominant Hodgkin lymphomaT-cell/histiocyte-rich large B-cell lymphomaB-cell lymphomaT cell populationsT-cell-rich B-cell lymphomaT-cell clonalityT cellsPeripheral bloodHodgkin lymphomaYounger patientsDiagnostic pitfallsB cellsSensitivity to PD-1 blockadeT-cell non-Hodgkin's lymphomaCD4+ T cell subsetsAberrant T-cell populationLymphocyte-predominant Hodgkin lymphomaT-cell-rich backgroundAggressive B-cell lymphomasLarge B-cell lymphomaRepertoire analysisAbnormal T-cell populationCohort of young patientsCD26- T cellsDiagnostic lymph nodesFrontline chemotherapy for CD30+ non-ALCL peripheral T-cell lymphoma a multi-center retrospective analysis
Trabolsi A, Han S, Johnson W, Stuver R, Lingamaneni P, Shastri T, Panjrolia E, Rojas-Neira E, Ayers A, Jayram D, Ho P, Treitman R, Chinniah S, Weiss J, Saeed H, Sethi T, Ganesan N, Chang T, Qureshi H, Haverkos B, Epstein-Peterson Z, Moskowitz A, Foss F, Malpica L, Bennani N, Ansell S, Zhang Y, Horwitz S, Schatz J. Frontline chemotherapy for CD30+ non-ALCL peripheral T-cell lymphoma a multi-center retrospective analysis. Blood 2025, 146: 3641. DOI: 10.1182/blood-2025-3641.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaECHELON-2 trialPTCL-TFHT-cell lymphomaCD30+PTCL-NOSCD30 expressionFrontline therapyRetrospective analysisMultivariate analysisFrontline regimenIPI scoreFrontline treatmentECHELON-2High-risk IPI scoreT-follicular helper phenotypeStage III-IV diseaseRetrospective pathology reviewBone marrow involvementLarge cell lymphomaIII-IV diseaseStage III/IV diseaseMedian Follow-UpSuperior outcomesMalignant T cellsPentostatin/TBI conditioning for allogeneic transplantation in T-cell lymphomas
Taborda C, Isufi I, Sethi T, Bar N, Gowda L, Wilson L, Girardi M, Roberts K, Seropian S, Foss F. Pentostatin/TBI conditioning for allogeneic transplantation in T-cell lymphomas. Blood 2025, 146: 2433. DOI: 10.1182/blood-2025-2433.Peer-Reviewed Original ResearchConceptsT-cell lymphomaTotal body irradiationGraft-versus-lymphomaOverall survivalComplete remissionRare subtypeT cellsConditioning regimensMedian OSChronic GVHDAllogeneic transplantationRemission statusCumulative incidenceCumulative incidence of grade II–IV acute GVHDIncidence of grade II-IV acute GVHDProspective evaluationCalcineurin inhibitor-based GVHD prophylaxisGrade II-IV acute GVHDLow-dose total body irradiationDonor typeReduced-intensity conditioning regimensAllogeneic stem cell transplantationAnaplastic large cell lymphomaPeripheral T-cell lymphomaAggressive T-cell lymphoma
Clinical Trials
Current Trials
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma
HIC ID2000038253RoleSub InvestigatorPrimary Completion Date12/31/2025Recruiting ParticipantsSoquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
HIC ID2000038321RoleSub InvestigatorPrimary Completion Date02/28/2026Recruiting ParticipantsStudy of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
HIC ID2000037506RoleSub InvestigatorPrimary Completion Date06/01/2025Recruiting ParticipantsPhase II Study of Mogamulizumab With DA-EPOCH in Patients With Aggressive T Cell Lymphoma
HIC ID2000037447RolePrincipal InvestigatorPrimary Completion Date11/30/2026Recruiting ParticipantsA Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
HIC ID2000037926RoleSub InvestigatorPrimary Completion Date04/28/2031Recruiting ParticipantsGenderBothAge5 years - 60 years
Academic Achievements & Community Involvement
Copy Link
Activities
activity Yale Cancer Center Protocol Review Committee (PRC)
2022 - PresentCommitteesMemberactivity Yale Affiliated Hospitals Program (YAHP)-Hematology
2022 - PresentCommitteesDirectoractivity New England Hematologic Malignancies Symposium
07/01/2023 - PresentMeeting Planning and ParticipationAbstract Revieweractivity British Journal of Hematology
10/01/2015 - PresentJournal ServiceRevieweractivity Bone Marrow Transplantation
10/01/2015 - PresentJournal ServiceReviewer
Honors
honor AACR/ASCO VAIL Methods in Clinical Cancer Research (MCCR)
07/27/2017National AwardDetailsUnited Stateshonor Abstract Achievement Award
11/01/2016National AwardAmerican Society of HematologyDetailsUnited Stateshonor Post Doctoral Fellowship in Translational Medicine and Therapeutics
07/01/2013National AwardPharmaceutical Research and Manufacturers of America (PhRMA) FoundationDetailsUnited Stateshonor Award for the highest score in the Internal Medicine in-service exam among PGY3 residents
06/30/2013Other AwardUniversity of LouisvilleDetailsUnited Stateshonor Award for the highest score in the Internal Medicine in- service exam among PGY2 residents
07/01/2012Other AwardUniversity of LouisvilleDetailsUnited States
Clinical Care
Copy Link
Overview
Tarsheen Sethi, MD, MSCI (master of science in clinical investigation), is a hematologist who specializes in treating patients with Hodgkin and non-Hodgkin lymphoma—cancers that begin in white blood cells called lymphocytes, which are an important part of the immune system.
An active researcher, Dr. Sethi focuses on treatments using new drugs and multi-drug combinations on all types of lymphomas. Some of her research addresses treatment of a rare category of lymphomas, hastening patient referrals, improving quality of life, and coordinating the use of different drugs.
As the understanding of cancer has become more specific and treatments more complex and targeted, Dr. Sethi has worked to help build a database of information on chemotherapy treatments that is shared freely throughout the world.
Clinical Specialties
Hematologic Oncology; Leukemia & Lymphoma; Hematology
Fact Sheets
Acute Myeloid Leukemia (AML)
Learn More on Yale MedicineDiagnosing Leukemia
Learn More on Yale MedicineCytogenic Studies for Leukemia Diagnosis
Learn More on Yale MedicineLeukemia in Children
Learn More on Yale Medicine
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews & Links
Copy Link
News
Related Links
Get In Touch
Copy Link
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.